

Get More Info From Immunexpress
SeptiCyte RAPID running on Idylla platform
About Our Organization
Immunexpress is a molecular diagnostic company, based in Brisbane and Seattle, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's dysregulated immune response by quantifying and analyzing gene expression from whole blood, providing actionable results in about an hour from sepsis suspicion, to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID is a lab test for sepsis that combines SeptiCyte® technology with the ease-of-use of the revolutionary Biocartis' Idylla™ Platform; it supports differentiating infection (bacterial, viral, fungal) positive sepsis that could lead to organ dysfunction and death from patients with less serious infection negative systemic inflammation. This powerful test enhances early sepsis detection and can strongly support its diagnosis in the crucial first hour(s) that determines clinical outcome. SeptiCyte® RAPID also has a high potential to reduce sepsis associated healthcare costs.
Enter Giveaway
Take our mini-quiz survey to get a $10 gift card with all answers correct!
Downloadable Handouts
-
SeptiCyte RAPID performance across a heterogeneous patient populationYou must log in to access content.
Booth Staff

There are no matching speakers.
Access Date | Quiz Result | Score | Actions |
---|